β-Caryophyllene

• Description :

  β-Caryophyllene is a CB2 receptor agonist.

• Product Name Alternative :

  (-) - (E) -Caryophyllene; (−) -β-caryophyllene; (−) -trans-Caryophyllene

• UNSPSC :

  12352211

• Hazard Statement :

  H302, H413

• Target :

  Cannabinoid Receptor; Endogenous Metabolite

• Type :

  Natural Products

• Related Pathways :

  GPCR/G Protein; Metabolic Enzyme/Protease; Neuronal Signaling

• Applications :

  Cancer-programmed cell death

• Field of Research :

  Cancer; Infection; Neurological Disease

• Assay Protocol :

  https://www.medchemexpress.com/_beta_-Caryophyllene.html

• Purity :

  99.75

• Solubility :

  DMSO : 25 mg/mL (ultrasonic) |Ethanol : ≥ 176.67 mg/mL|H2O : < 0.1 mg/mL

• Smiles :

  C=C1CC/C=C(C)/CC[C@@]2([H])C(C)(C)C[C@]12[H]

• Molecular Formula :

  C15H24

• Molecular Weight :

  204.35

• Precautions :

  H302, H413

• References & Citations :

  [1]Cheng Y, et al. β-Caryophyllene ameliorates the Alzheimer-like phenotype in APP/PS1 Mice through CB2 receptor activation and the PPARγ pathway. Pharmacology. 2014;94 (1-2) :1-12.|[2]Dahham SS, et al. The Anticancer, Antioxidant and Antimicrobial Properties of the Sesquiterpene β-Caryophyllenefrom the Essential Oil of Aquilaria crassna. Molecules. 2015 Jun 26;20 (7) :11808-29.|[3]de Oliveira CC, et al. Anticonvulsant activity of β-caryophyllene against pentylenetetrazol-induced seizures. Epilepsy Behav. 2016 Mar;56:26-31.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Natural Products

• Clinical Information :

  Phase 3

• Isoform :

  Human Endogenous Metabolite

• Citation 01 :

  Int J Mol Sci. 2025 May 7;26 (9) :4430.|Neuropharmacology. 2025 Oct 28:283:110752.|Phytomedicine.|SSRN. 2025 Jun 13.|Metab Brain Dis. 2025 Oct 30;40 (8) :301.

• CAS Number :

  [87-44-5]